Notice to stakeholders: Considerations regarding the proposed use of psilocybin mushrooms in clinical trials, or as a drug accessed through the Special Access Program (SAP)

Health Canada is aware of the growing interest in the use of psilocybin, including psilocybin that occurs naturally in certain mushroom species, for potential therapeutic purposes. In response, Health Canada is issuing this notice to provide information on the use of psilocybin mushrooms in clinical trials or as a drug requested through the Special Access Program (SAP), and to emphasize the importance of drug quality and Good Manufacturing Practices (GMP).

Data and Resources

Additional Info

Field	Value
Last Updated	April 17, 2026, 17:42 (UTC)
Created	April 17, 2026, 17:42 (UTC)
criticality_level	[]
geographic_scope	[]
open_canada_collection	publication
open_canada_date_published	2022-05-04 00:00:00
open_canada_keywords	{"fr": ["avis aux parties prenantes", "psilocybine", "espèces de champignons", "utilisation de la psilocybine", "programme d'accès spécial", "SAP", "médicament accessible via SAP"], "en": ["notice to stakeholders", "psilocybin", "mushroom species", "use of psilocybin", "special access program", "SAP", "drug accessed through-SAP"]}
open_canada_subject	["health_and_safety"]
sensitivity_level	unrestricted
title_fr	Avis aux intervenants : Considérations concernant l’utilisation proposée des champignons à psilocybine dans les essais cliniques ou en tant que médicament auquel on accède par le biais du Programme d’accès spécial (PAS)
update_frequency	as_needed